Therefore, a subgroup analysis of this study based on Asian patients with HER2-positive advanced BC who failed ≥ 2 HER2-targeted therapies was performed, revealing the same efficacy characteristics in Asian patients as in the entire study population; thus, Asian patients could also significantly benefit from neratinib plus capecitabine, with no new security issues having been observed(Dai et al. 2021). This evidence concerns the gene ERBB2 and breast cancer.